New FTC Task Force Seeks Public Input On Drug Merger Evaluations

By Gabrielle Wanneh / May 13, 2021 at 2:21 PM
A new working group at the Federal Trade Commission is seeking public input on the commission’s reviews of drug industry mergers, which are becoming more common and have raised concerns about anticompetitive conduct. “Public input is critical to the process of refreshing our approach to pharmaceutical mergers,” said FTC Acting Chair Rebecca Slaughter. “In the face of skyrocketing drug prices and ongoing concerns about anticompetitive conduct by pharmaceutical companies, we need to ensure that our investigations fully capture the potential...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.